Make Better Decisions

  • Identify first generic entrants
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Farmers Insurance
Fish and Richardson
Express Scripts
Boehringer Ingelheim
Federal Trade Commission

Generated: November 18, 2017

DrugPatentWatch Database Preview

Details for Patent: 7,364,752

« Back to Dashboard

Which drugs does patent 7,364,752 protect, and when does it expire?

Patent 7,364,752 protects VIEKIRA PAK (COPACKAGED), VIEKIRA XR, KALETRA, NORVIR, and TECHNIVIE, and is included in five NDAs. There have been zero Paragraph IV challenges on Kaletra and Norvir

Protection for KALETRA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

Summary for Patent: 7,364,752

Title:Solid dispersion pharamaceutical formulations
Abstract:A pharmaceutical composition is disclosed which comprises a solid dispersion of an HIV protease inhibitor in a water soluble carrier, such as PEG, having enhanced bioavailability and improved dissolution properties. The solid dispersion may optionally be encapsulated in hard gelatin capsules, compressed into a tablet, or may be granulated with a pharmaceutically acceptable granulating agent. Also disclosed are methods of making said solid dispersion and methods of treating an HIV infection employing said solid dispersion.
Inventor(s): Fort; James J. (Midlothian, VA), Krill; Steven L. (Chatham, NJ), Law; Devalina (Libertyville, IL), Qiu; Yihong (Gurnee, IL), Porter; William R. (Vernon Hills, IL), Schmitt; Eric A. (Libertyville, IL)
Assignee: Abbott Laboratories (Abbott Park, IL)
Application Number:09/709,829
Patent Claim Types:
see list of patent claims
Composition; Dosage form; Delivery; Use;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Abbvie Inc
dasabuvir sodium ; ombitasvir; paritaprevir; ritonavir
TABLET, TABLET;ORAL206619-001Dec 19, 2014RXYesYes► Subscribe► SubscribeY
Abbvie Inc
dasabuvir sodium; ombitasvir; paritaprevir; ritonavir
TABLET, EXTENDED RELEASE;ORAL208624-001Jul 22, 2016RXYesYes► Subscribe► SubscribeY
lopinavir; ritonavir
TABLET;ORAL021906-002Nov 9, 2007RXYesNo► Subscribe► SubscribeY
lopinavir; ritonavir
TABLET;ORAL021906-001Oct 28, 2005RXYesYes► Subscribe► SubscribeY
TABLET;ORAL022417-001Feb 10, 2010ABRXYesYes► Subscribe► SubscribeY
Abbvie Inc
ombitasvir; paritaprevir; ritonavir
TABLET;ORAL207931-001Jul 24, 2015RXYesYes► Subscribe► SubscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Queensland Health
Daiichi Sankyo
US Army
Chinese Patent Office

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

Google Plus